Summary摘要
Primarybiliarycholangitis(PBC)isachronicinflammatoryautoimmunecholestaticliverdisease,whichwhenuntatedwillculminateinend-stagebiliarycirrhosis.Diagnosisisusuallybasedonthepsenceofserumlivertestsindicativeofacholestatichepatitisinassociationwithcirculatingantimitochondrialantibodies.
原发性胆汁性胆管炎(PBC)是一种慢性炎症性胆汁郁积的自身免疫性肝病,如不经治疗可进展为晚期胆汁性肝硬化。诊断通常基于胆汁郁积的血清学依据及血清抗线粒体抗体(AMA)。
Patientpsentationandcoursecanbediverseandriskstratificationisimportanttoensuallpatientsceiveapersonalisedapproachtotheirca.Thegoalsoftatmentandmanagementathepventionofend-stageliverdisease,andtheameliorationofassociatedsymptoms.Pharmacologicapproachesinpractice,toducetheimpactoftheprogssivenatuofdisease,curntlyincludelicensedtherapies(ursodeoxycholicacidandobeticholicacid)andoff-labeltherapies(fibricacidderivatives,budesonide).
患者的临床表现多样,将疾病进行危险分层有助于进行个体化治疗,而治疗及管理的目标则是防止进展为晚期肝病和改善临床症状。为延缓疾病的自然进程,目前的治疗方案包括已认可的(熊去氧胆酸和奥贝胆酸)和没被临床认可的(纤维酸衍生物和布地奈德)。
Theseclinicalpracticeguidelinessummarisetheevidencefortheimportanceofastructud,life-longandindividualised,approachtothecaofpatientswithPBC,providingaframeworktohelpcliniciansdiagnoseandeffectivelymanagepatients.
本指南总结了对PBC病人结构化、终生及个体化治疗的重要证据,为临床医生诊断及高效的管理病人提供了一个框架。